Pemetrexed

Generic Name
Pemetrexed
Brand Names
Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
Drug Type
Small Molecule
Chemical Formula
C20H21N5O6
CAS Number
137281-23-3
Unique Ingredient Identifier
04Q9AIZ7NO
Background

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication

Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions
Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
Associated Therapies
Monotherapy
Clinical Trials
Related News

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

First Posted Date
2019-06-06
Last Posted Date
2024-11-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
672
Registration Number
NCT03976323
Locations
🇺🇸

Renovatio Clinical ( Site 0062), The Woodlands, Texas, United States

🇦🇺

Liverpool Hospital ( Site 1201), Liverpool, New South Wales, Australia

🇨🇦

Stronach Regional Cancer Centre ( Site 0101), Newmarket, Ontario, Canada

and more 175 locations

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

First Posted Date
2019-06-03
Last Posted Date
2024-06-14
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
166
Registration Number
NCT03971474
Locations
🇺🇸

Bayhealth Hospital Kent Campus, Dover, Delaware, United States

🇺🇸

Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States

🇺🇸

Riverside Methodist Hospital, Columbus, Ohio, United States

and more 882 locations

Pemetrexed for the Treatment of Chordoma

Phase 1
Completed
Conditions
Chordoma
Interventions
Drug: Pemetrexed
First Posted Date
2019-05-17
Last Posted Date
2023-03-07
Lead Sponsor
Saint John's Cancer Institute
Target Recruit Count
15
Registration Number
NCT03955042
Locations
🇺🇸

John Wayne Cancer Institute, Santa Monica, California, United States

A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2019-05-16
Last Posted Date
2023-08-08
Lead Sponsor
Shanghai Henlius Biotech
Target Recruit Count
643
Registration Number
NCT03952403
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

First Posted Date
2019-05-15
Last Posted Date
2024-06-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
40
Registration Number
NCT03950674
Locations
🇯🇵

National Hospital Organization Nagoya Medical Center ( Site 0324), Nagoya, Aichi, Japan

🇯🇵

The Cancer Institute Hospital of JFCR ( Site 0323), Tokyo, Japan

🇯🇵

Kurume University Hospital ( Site 0326), Kurume, Fukuoka, Japan

and more 7 locations

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

First Posted Date
2019-05-10
Last Posted Date
2024-07-17
Lead Sponsor
AstraZeneca
Target Recruit Count
248
Registration Number
NCT03944772
Locations
🇸🇪

Research Site, Stockholm, Sweden

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

First Posted Date
2019-04-19
Last Posted Date
2020-04-24
Lead Sponsor
Incyte Corporation
Registration Number
NCT03920839

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

First Posted Date
2019-04-17
Last Posted Date
2024-12-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
230
Registration Number
NCT03918278
Locations
🇺🇸

Next Oncology ( Site 0001), San Antonio, Texas, United States

🇨🇦

Princess Margaret Cancer Centre ( Site 0011), Toronto, Ontario, Canada

🇨🇦

BC Cancer - Vancouver Center ( Site 0010), Vancouver, British Columbia, Canada

and more 13 locations

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

First Posted Date
2019-04-11
Last Posted Date
2020-09-17
Lead Sponsor
Biocad
Target Recruit Count
292
Registration Number
NCT03912389
Locations
🇨🇿

Regional Hospital Liberec, Liberec, Czechia

🇨🇿

University Hospital Olomouc, Olomouc, Czechia

🇨🇿

University Hospital Ostrava, Ostrava, Czechia

and more 34 locations

Pan Tumor Rollover Study

First Posted Date
2019-04-02
Last Posted Date
2024-11-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1500
Registration Number
NCT03899155
Locations
🇧🇷

Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil

🇨🇳

Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China

🇨🇳

Local Institution - 0172, Changsha, Hunan, China

and more 304 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy